Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5467)
All Articles published online
|
Publishing Process of This Article
|
Feb 15, 2014 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Franco DR, Baptista J, Abreu FR, Batista RB, Eliaschewitz FG. Starting glargine in insulin-naïve type 2 diabetic patients based on body mass index is safe. World J Diabetes 2014; 5(1): 69-75 [PMID: 24567803 DOI: 10.4239/wjd.v5.i1.69] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v5/i1/69.htm |
| Number | Citing Articles |
| 1 |
Linong Ji, Hailong Wan, Binhong Wen, Xueying Wang, Junfen Wang, Rongwen Bian, Wuyan Pang, Jian Tian, Yan Wang, Fang Bian, Zhengnan Gao, Alex Condoleon, Wei Feng, Xia Zhang, Nan Cui. Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open‐label, randomized controlled trial (BEYOND VII). Diabetes, Obesity and Metabolism 2020; 22(5): 838 doi: 10.1111/dom.13967
|
| 2 |
Linong Ji, Zhengnan Gao, Bimin Shi, Rongwen Bian, Fuzai Yin, Wuyan Pang, Hong Gao, Nan Cui. Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Randomized Controlled Trial. Advances in Therapy 2018; 35(6): 864 doi: 10.1007/s12325-018-0717-x
|